Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PREVU* life insurance trial

This article was originally published in The Tan Sheet

Executive Summary

A 25,000-patient study evaluating PREVU* LT in the life insurance testing market is expected to begin in the second quarter of 2005, International Medical Innovations announces May 10. The PREPARE study (PREVU Predicts Atherosclerosis Risk & Events) will test life insurance applicants with the product and compare the results to "traditional risk assessment measures," IMI says. PREVU* LT is the lab-processed version of the company's skin sterol test, which measures cholesterol levels by testing skin tissues. Entering the insurance market offers an opportunity to the firm because a "significant number" of the 13.5 mil. individuals who purchased life insurance policies in 2003 did not have a cardiovascular disease assessment, IMI says. The company reached a licensing agreement last year with McNeil's consumer division that includes working to develop an OTC version of the product (1"The Tan Sheet" June 7, 2004, p. 10)...

You may also be interested in...

McNeil Reaches Consumer Cholesterol Testing Licensing Deal With IMI

McNeil Consumer Health is seeking to leverage the potential Rx-to-OTC switch of J&J/Merck's Mevacor (lovastatin) with an agreement to license International Medical Innovations' predictive tests for coronary artery disease (CAD)

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.

Finance Watch: 2020 IPOs Surpass 2019 Total With 52 To Date

ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts